Spots Global Cancer Trial Database for vegfr
Every month we try and update this database with for vegfr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | NCT01930006 | Advanced Malign... | MGCD265 | 18 Years - 55 Years | Mirati Therapeutics Inc. | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| Safety Study of X-82 in Patients With Advanced Solid Tumors | NCT01296581 | Advanced Solid ... | X-82 | 18 Years - | Tyrogenex | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | NCT01496313 | Thyroid Cancer | 300mg vandetani... 150mg vandetani... | 18 Years - | Sanofi | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Safety Study of X-82 in Patients With Advanced Solid Tumors | NCT01296581 | Advanced Solid ... | X-82 | 18 Years - | Tyrogenex | |
| Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma | NCT01266707 | Hepatocellular ... | antiangiogenic ... | 20 Years - 80 Years | Fukushima Medical University | |
| Advanced Refractory Solid Tumors With TP53 Mutations Register Study | NCT03927599 | Solid Tumor, Ad... | Data Collection | 18 Years - | Tianjin Medical University Second Hospital | |
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | NCT00090545 | Prostate Cancer | BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | NCT03903705 | Advanced Solid ... | Fruquintinib in... | 18 Years - 75 Years | Hutchmed | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of X-82 in Patients With Advanced Solid Tumors | NCT01296581 | Advanced Solid ... | X-82 | 18 Years - | Tyrogenex | |
| HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1) | NCT01266720 | Pancreatic Canc... | VEGFR1, VEGFR2 Gemcitabine | 20 Years - 80 Years | Fukushima Medical University | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | NCT01930006 | Advanced Malign... | MGCD265 | 18 Years - 55 Years | Mirati Therapeutics Inc. | |
| Study of Oral AEE788 in Adults With Advanced Cancer | NCT00118456 | Cancer | AEE788 | 18 Years - | Novartis | |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations | NCT02747797 | Advanced Cancer | Lucitanib | 18 Years - | University of California, San Diego |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
